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SUPPLEMENTARY NOTES
ABSTRACT
Loss of the stromal TGF-β signaling in the prostate has been shown to initiate prostate cancer (PCa), promote PCa progression, and facilitate the development of mixed osteoblastic/osteolytic bone lesions. However, the effects on bone lesions are found to be transient. We thus focused on delineating the context-dependent role of TGF-β signaling in the bone microenvironment effects on PCa bone lesions. Using genetic engineered mouse models, TGF-β signaling is cell-specifically knockout (KO) in the prostate fibroblasts and osteoblasts in the bone by Col cre /Tgfbr2 KO, or in the myeloid lineage cells, including osteoclasts in the bone by LysM cre /Tgfbr2 KO. Compared the PCa-induced bone lesions in the KO mice tibiae to the lesions in the Flox mice, we found that PC3-induced osteolytic bone lesions were significantly increased by Col cre /Tgfbr2 KO, but were significantly decreased by LysM cre /Tgfbr2 KO. Our findings suggested that osteoblastic TGF-β signaling inhibits PCa bone lesions development, but myeloid TGF-β signaling promotes PCa bone lesion development. We further found that basic FGF mediated the effect of increased PC3 bone lesions in Col cre /Tgfbr2 KO mice. 
Appendices…………………………………………………………... N/A
Introduction:
The hypothesis of this proposal is that cytokines/chemokines regulated by stromal TGF-β signaling from the primary tumor microenvironment dictate prostate cancer (PCa) osteoblastic bone metastasis. We proposed to determine the contribution of prostate stromal TGF-β in PCainduced osteoblastic bone lesion development and to determine the chemokines that induced by loss of TGF-β signaling mediate PCa blastic bone metastasis. However, we found that although loss of TGF-β responsiveness in prostate stromal cells do alter chemokine levels and facilitate the development of mixed osteoblastic/osteolytic bone lesions, these effects are transient (Li, 2012) . These results suggest that it is the interactions between the dessminated PCa cells and the cells in the bone microenvironment determined the bone lesion development. More important, 70% of PCa patients have detectable tumor cells in the bone barrow at the time of initial diagnosis, and we know 13% of PCa patients each year after a long period of tumor dormancy, most of these patient (70-90%) have bone metastasis (Morgan, 2009; Siegel, 2014) . Therefore, we are now focusing on determining how the bone microenvironment effects on PCa bone metastasis. We thus proposed that the bone microenvironment is the final determinant for PCa induced bone lesion; the influence of cell-specific TGF-β signaling in the bone microenvironment might be different on PCa bone lesion development; and bFGF is one of the downstream mediators for the cell-specific TGF-β signaling effect that can be targeted to reduce bone lesions.
To test these hypotheses, we have used inducible TGF-β type II receptor (TβRII) knockout (Tgfbr2 KO) mouse models. Col1 creERT /Tgfbr2 KO (Col/Tgfbr2 KO), which have TGF-β signaling specific KO in fibroblasts and osteoblasts, and LysM cre /Tgfbr2 KO (LysM/Tgfbr2 KO), which have TGF-β signaling specific KO in cells of myeloid lineage, such as osteoclast in the bone. These inducible mouse models were generated in Rag2 -/-immunodeficient background, so that human PCa cells are able to xenografted into these mice. The mice were further crossed with mT/mG reporter mouse from Jackson Laboratory. Therefore the specific Cre expression can be determined through immunohistochemistry (IHC) using anti-GFP antibody in decalcified mouse bone tissues . To determine the cell specific role of TGF-β signaling in the bone microenvironment effects on PCa bone lesions (months 12-18): Task 1. Characterization of the above genetic-engineered mice: The bones are normal compared to the control floxed mice by x-ray and microCT analysis .
Task 2. Effects on PCa bone lesions:
2a. PC3 PCa-induced osteolytic bone lesion development was significantly promoted in the Col cre /Tgfbr2 KO mice relative to Tgfbr2 Flox (control) mice (Figure 1) . The effect was repeated in DU145 cells (Figure 2) . Further analysis of the bone lesions, we found the increased bone lesions were presented with increased angiogenesis and proliferation of the tumor cells in the bone, and osteoclastogenesis (Figure 3) .
2b. LysM
cre /Tgfbr2 KO significantly decreased PC3-induced bone lesions (Figure 4 ).
2c. Consistent with the data in PC3 cells, LUCaP tumor induced osteoblastic bone lesions were inhibited by LysM/Tgfbr2 KO. More importantly, the bone lesion development in LysM/Tgfbr2 KO (but not in the Col/Tgfbr2 KO mouse), if it happens, takes additional 4 weeks to be detected; suggesting LysM/Tgfbr2 KO induced LUCaP PCa dormancy (Figure 5) . Therefore, we propose loss of TGF-β signaling only in cells of the myeloid lineage creates a dormancy-permissive bone microenvironment for PCa cells. To determine the downstream mediator for cell specific role of TGF-β signaling in the bone microenvironment effects on PCa bone lesion devleopment (months 18-24): Task 3. Downstream mediators of TGF-β signaling in cells of the osteoblast lineage for inhibiting PCa bone lesion development: 3a. Basic fibroblast growth factor (bFGF) in PC3 bone metastasis: bFGF was identified by cytokine array screening and confirmed to have increased expression at both mRNA level and protein level in PC3 induced tibiae of Col/Tgfbr2 KO relative to control mice. IHC revealed that the bFGF was expressed mainly in osteoblasts and FGFR1 in PC3 cells, which were all increased in the lesions from Col/Tgfbr2 KO mouse bone relative to control mouse (Figure 6 ). 4a. For promoting PC3 bone lesions: Cytokine array analysis showed the most up-regulated cytokines in the PC3 LysM cre /Tgfbr2 KO tibiae compared to the control tibiae were: IL-28, AXL, IL6R, IL10, HGF, IL-6, Fas ligand and Growth arrest specific 1. We are currently further investigating the specific role of these factors.
4b. For promoting LUCaP PCa dormancy: We found a critical piece of the LysM cre /Tgfbr2 KO mouse bone microenvironment is the expression of claudin-19 (Cldn19) in osteoblasts, in establishing a dormancy-permissive microenvironment for PCa cells. Claudins are the primary integral membrane proteins that form tight junctions, whose functions include forming cell adhesions, controlling cell permeability, and inhibiting cell proliferation. We have found that in order for Cldn19 to be expressed in osteoblasts, DNA demethylation is likely required. Thus, we hypothesize that loss of myeloid-specific TGF-β signaling activates Cldn19 expression in osteoblasts, leading to a growth-inhibitory bone microenvironment for PCa cells. A proposal for DOD idea award was submitted based on these exciting findings.
Therefore, we conclude that bFGF is a mediator for TGF-β signaling in osteoblasts on inducing osteolytic, but not osteoblastic PCa bone lesion development; Cldn19 expression in osteoblasts sets up a dormancy permissive bone microenvironment for osteoblastic PCa cells.
To determine whether the downstream mediators of cell specific TGF-β signaling in the bone microenvironment can be targeted for reducing PCa bone lesions (months 20-24): Figure  7A, B&C) . These effects were correlated with respective changes in FGFR1, FGFR4, and p-AKT in the bone lesions ( Figure 7D ).
